Bristol-Myers Squibb Company
Bristol-Myers Squibb Company
430 E. 29th Street, 14th Floor,
New York, NY 10016
Phone: 1-800-332-2056Website: https://www.bms.com/Careers: www.bms.com/careers/Pages/home.aspxPatient Assistance Program: www.bms.com/products/Pages/programs.aspx
Latest news
- U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
3 October 2024 - FDA Approves Cobenfy (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
27 September 2024 - FDA Approves Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
13 June 2024 - U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
30 May 2024 - Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
15 May 2024 - Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
6 April 2024 - Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
6 April 2024 - U.S. FDA Approves Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
5 April 2024 - U.S. FDA Approves Bristol Myers Squibb’s Breyanzi as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
14 March 2024 - U.S. Food and Drug Administration Approves Opdivo (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
7 March 2024
Drugs Associated with Bristol-Myers Squibb Company
Bristol-Myers Squibb Company manufactures, markets and/or distributes more than 34 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Abecma
Generic name: idecabtagene vicleucel Drug class: miscellaneous antineoplastics |
||
|
Abraxane
Generic name: paclitaxel protein-bound Drug class: mitotic inhibitors |
5 reviews | 6.2 / 10 |
|
Augtyro
Generic name: repotrectinib Drug class: multikinase inhibitors |
||
|
Azactam
Generic name: aztreonam Drug class: miscellaneous antibiotics |
||
|
Baraclude
Generic name: entecavir Drug class: nucleoside reverse transcriptase inhibitors (NRTIs) |
1 review | 10 / 10 |
|
Breyanzi
Generic name: lisocabtagene maraleucel Drug class: miscellaneous antineoplastics |
||
|
Camzyos
Generic name: mavacamten Drug class: miscellaneous cardiovascular agents |
3 reviews | 10 / 10 |
|
Cobenfy
Generic name: trospium/xanomeline |
||
|
Droxia
Generic name: hydroxyurea Drug class: antimetabolites |
||
|
Eliquis
Generic name: apixaban Drug class: factor Xa inhibitors |
210 reviews | 5.2 / 10 |
|
Empliciti
Generic name: elotuzumab Drug class: miscellaneous antineoplastics |
||
|
Evotaz
Generic name: atazanavir/cobicistat Drug class: antiviral combinations |
||
|
Hydrea
Generic name: hydroxyurea Drug class: antimetabolites |
8 reviews | 7.2 / 10 |
|
Idhifa
Generic name: enasidenib Drug class: miscellaneous antineoplastics |
||
|
Inrebic
Generic name: fedratinib Drug class: multikinase inhibitors |
||
|
Istodax
Generic name: romidepsin Drug class: histone deacetylase inhibitors |
1 review | 1.0 / 10 |
|
Kenalog-10
Generic name: triamcinolone Drug class: glucocorticoids |
20 reviews | 7.8 / 10 |
|
Kenalog-40
Generic name: triamcinolone Drug class: glucocorticoids |
109 reviews | 6.3 / 10 |
|
Nulojix
Generic name: belatacept Drug class: selective immunosuppressants |
1 review | 10 / 10 |
|
Onureg
Generic name: azacitidine Drug class: miscellaneous antineoplastics |
||
|
Opdivo
Generic name: nivolumab Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors) |
77 reviews | 5.3 / 10 |
|
Opdualag
Generic name: nivolumab/relatlimab Drug class: antineoplastic combinations |
||
|
Orencia
Generic name: abatacept Drug class: antirheumatics, selective immunosuppressants |
66 reviews | 6.0 / 10 |
|
Pomalyst
Generic name: pomalidomide Drug class: miscellaneous antineoplastics, other immunosuppressants |
3 reviews | 10 / 10 |
|
Reblozyl
Generic name: luspatercept Drug class: miscellaneous erythropoiesis agents |
5 reviews | 9.6 / 10 |
|
Revlimid
Generic name: lenalidomide Drug class: miscellaneous antineoplastics, other immunosuppressants |
22 reviews | 7.0 / 10 |
|
Reyataz
Generic name: atazanavir Drug class: protease inhibitors |
4 reviews | 8.8 / 10 |
|
Sotyktu
Generic name: deucravacitinib Drug class: multikinase inhibitors |
11 reviews | 6.0 / 10 |
|
Sprycel
Generic name: dasatinib Drug class: BCR-ABL tyrosine kinase inhibitors |
21 reviews | 7.5 / 10 |
|
Sustiva
Generic name: efavirenz Drug class: NNRTIs |
6 reviews | 5.2 / 10 |
|
Thalomid
Generic name: thalidomide Drug class: leprostatics, miscellaneous antineoplastics, other immunosuppressants |
||
|
Vidaza
Generic name: azacitidine Drug class: miscellaneous antineoplastics |
13 reviews | 5.5 / 10 |
|
Yervoy
Generic name: ipilimumab Drug class: anti-CTLA-4 monoclonal antibodies |
2 reviews | 9.5 / 10 |
|
Zeposia
Generic name: ozanimod Drug class: selective immunosuppressants |
5 reviews | 8.0 / 10 |
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||